NASDAQ:AIMT - Aimmune Therapeutics Stock Price, Forecast & News

Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."

Aimmune Therapeutics Inc (NASDAQ:AIMT) announced its quarterly earnings data on Wednesday, November, 6th. The biotechnology company reported ($1.03) EPS for the quarter, hitting the consensus estimate of ($1.03). During the same quarter in the prior year, the business posted ($0.89) earnings per share. View Aimmune Therapeutics' Earnings History.

Aimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Aimmune Therapeutics.

Aimmune Therapeutics will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

11 brokers have issued twelve-month price targets for Aimmune Therapeutics' stock. Their forecasts range from $27.00 to $81.00. On average, they expect Aimmune Therapeutics' stock price to reach $48.82 in the next year. This suggests a possible upside of 85.9% from the stock's current price. View Analyst Price Targets for Aimmune Therapeutics.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aimmune Therapeutics.

Press coverage about AIMT stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aimmune Therapeutics earned a news impact score of 0.6 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Aimmune Therapeutics.

Aimmune Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 11,570,000 shares, an increase of 6.4% from the January 15th total of 10,870,000 shares. Based on an average daily trading volume, of 888,400 shares, the days-to-cover ratio is presently 13.0 days. Currently, 29.0% of the shares of the company are short sold. View Aimmune Therapeutics' Current Options Chain.

Some companies that are related to Aimmune Therapeutics include Reata Pharmaceuticals (RETA), The Medicines (MDCO), Horizon Therapeutics (HZNP), Amarin (AMRN), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Evotec (EVTCY), Nektar Therapeutics (NKTR), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals PLC- (GWPH), FibroGen (FGEN), Mirati Therapeutics (MRTX), Agios Pharmaceuticals (AGIO) and Blueprint Medicines (BPMC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), Alibaba Group (BABA), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), CA (CA), Amarin (AMRN), Brainstorm Cell Therapeutics (BCLI), BlackRock (BLK) and Roku (ROKU).

(AIMT) raised $124 million in an initial public offering (IPO) on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO.

Aimmune Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Palo Alto Investors LP (5.39%), FMR LLC (4.59%), State Street Corp (3.51%), Victory Capital Management Inc. (3.44%), Victory Capital Management Inc. (3.41%) and Alliancebernstein L.P. (3.30%). Company insiders that own Aimmune Therapeutics stock include Bakker Juliet Tammenoms, Daniel C Md Adelman, Douglas T Sheehy, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg, Mary M Rozenman, Patrick G Enright and Stephen George Dilly. View Institutional Ownership Trends for Aimmune Therapeutics.

AIMT stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Massachusetts Financial Services Co. MA, Palo Alto Investors LP, UBS Group AG, Alliancebernstein L.P., State of New Jersey Common Pension Fund D, Citigroup Inc. and Rice Hall James & Associates LLC. Company insiders that have sold Aimmune Therapeutics company stock in the last year include Daniel C Md Adelman and Douglas T Sheehy. View Insider Buying and Selling for Aimmune Therapeutics.

AIMT stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., State Street Corp, FMR LLC, Fiera Capital Corp, New York State Common Retirement Fund, Bank of America Corp DE and Geode Capital Management LLC. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Bakker Juliet Tammenoms, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg and Patrick G Enright. View Insider Buying and Selling for Aimmune Therapeutics.

Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AIMT stock can currently be purchased for approximately $26.26.

Aimmune Therapeutics has a market capitalization of $1.65 billion. The biotechnology company earns $-210,750,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. Aimmune Therapeutics employs 228 workers across the globe.View Additional Information About Aimmune Therapeutics.

The official website for Aimmune Therapeutics is http://www.aimmune.com/.

Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected]